Robless PA - Search Results

1

Lumbar spine bone mineral density predicts endothelial reactivity in patients with systemic lupus erythematosus.

Mak A, Ling LH, Ho RC, Gong L, Cheak AA, Yee H, Vasoo S, Koh DR, Robless PA. Mak A, et al. Among authors: robless pa. Clin Exp Rheumatol. 2011 Mar-Apr;29(2):261-8. Epub 2011 Apr 19. Clin Exp Rheumatol. 2011. PMID: 21385541

2

Cilostazol for peripheral arterial disease.

Robless P, Mikhailidis DP, Stansby GP. Robless P, et al. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003748. doi: 10.1002/14651858.CD003748.pub3. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2014 Oct 31;(10):CD003748. doi: 10.1002/14651858.CD003748.pub4 PMID: 18254032 Updated. Review.

3

Cilostazol for peripheral arterial disease.

Robless P, Mikhailidis DP, Stansby GP. Robless P, et al. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003748. doi: 10.1002/14651858.CD003748.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003748. doi: 10.1002/14651858.CD003748.pub3 PMID: 17253494 Updated. Review.

4

Chronic brainstem ischemia in subclavian steal syndrome.

Sharma VK, Chuah B, Teoh HL, Chan BP, Sinha AK, Robless PA. Sharma VK, et al. Among authors: robless pa. J Clin Neurosci. 2010 Oct;17(10):1339-41. doi: 10.1016/j.jocn.2010.03.019. J Clin Neurosci. 2010. PMID: 20620065

5

Antiplatelet agents for intermittent claudication.

Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Wong PF, et al. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD001272. doi: 10.1002/14651858.CD001272.pub2. Cochrane Database Syst Rev. 2011. PMID: 22071801 Review.

6

Cilostazol for intermittent claudication.

Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Bedenis R, et al. Cochrane Database Syst Rev. 2014 Oct 31;2014(10):CD003748. doi: 10.1002/14651858.CD003748.pub4. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2021 Jun 30;6:CD003748. doi: 10.1002/14651858.CD003748.pub5 PMID: 25358850 Free PMC article. Updated. Review.

7

Dextran 40 reduces in vitro platelet aggregation in peripheral arterial disease.

Robless P, Okonko D, Mikhailidis DP, Stansby G. Robless P, et al. Platelets. 2004 Jun;15(4):215-22. doi: 10.1080/09537100410001682814. Platelets. 2004. PMID: 15203712 Free article.

8

Increased platelet aggregation and activation in peripheral arterial disease.

Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Robless PA, et al. Eur J Vasc Endovasc Surg. 2003 Jan;25(1):16-22. doi: 10.1053/ejvs.2002.1794. Eur J Vasc Endovasc Surg. 2003. PMID: 12525806 Free article.

9

Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease.

Robless P, Mikhailidis DP, Stansby G. Robless P, et al. Br J Surg. 2001 Jun;88(6):787-800. doi: 10.1046/j.0007-1323.2001.01774.x. Br J Surg. 2001. PMID: 11412247 Review.

10

Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40.

Robless PA, Tegos TJ, Okonko D, Mansfield AO, Nicolaides AN, Mikhailidis DP, Stansby G. Robless PA, et al. Platelets. 2002 Jun;13(4):231-9. doi: 10.1080/09537100220144849. Platelets. 2002. PMID: 12189025 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters